ONCOLOGY PROFILES/COMBINATIONS AND OPTIONS
ONCOLOGY PROFILES/COMBINATIONS AND OPTIONS
Any profile component may be ordered
individually on the LabCorp request form.
Combination of tests may be
configured as custom profiles.
Contact your local LabCorp facility. See
Profile Policy Statement.
See the Comprehensive List of Procedures for CPT information.
Acute Leukemia Profile, Flow Cytometry . . . . 489055
Profile Includes
Four-color immunophenotyping with CD45 gating for the
following markers: CD2, CD3, CD7, CD10, CD11b, CD13, CD14, CD15, CD19, CD20,
CD33, CD34, CD45, CD71, CD117, HLA-DR
Additional markers added as determined by pathologist
(CD1a, cCD3, CD4, CD5, CD8, cCD22, CD61, glycophorin A, TdT). Fewer markers will
be analyzed when specimen cellularity is limited.
Specimen Requirement 3 mL
EDTA whole blood (lavender), free from hemolysis, or 2 mL heparinized or EDTA
bone marrow aspirate (green or lavender). Submit at room temperature using
Leukemia/Lymphoma Specimen Transport Kit (supplied by LabCorp). Draw specimen so
it will arrive in the laboratory Monday through Saturday and within 24 hours of
collection. Maintain specimens at room temperature. Please state the date and
time of collection and the name and telephone/fax number of the physician to
whom results are to be called/transmitted on the request form. Please direct
any questions regarding this test to Oncology Customer Service at 800-533-0567,
ext 4060. Pathologist consultation is available Monday through Friday. Indicate
differential diagnosis on the request form. Submit recent CBC results for
inclusion in report if not submitting whole blood.
Breast Cancer Monitor Profile II . . . . 485003
Profile Includes
CA 27.29, Serial Monitor Report
Carcinoembryonic Antigen (CEA), Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. It a tube other than a
red-top tube is used, transfer the separated serum to a plastic transport tube.
The account must submit the patient's Social Security number to monitor. State
on the request form whether the patient is a smoker or nonsmoker. Values
obtained with different assay methods should not be used interchangeably in
serial testing. It is recommended that only one assay method be used
consistently to monitor each patient's course of therapy.
Breast Cancer Prognosis Profile I
(Paraffin Block) . . . . 480335
Profile Includes
DNA Ploidy Analysis
Estrogen/Progesterone Receptor (ER/PR) Assay
Specimen Requirement
Tumor (formalin-fixed, paraffin-embedded) in paraffin block transport pouch.
Specimen should be fixed in 10% neutral-buffered formalin within 20 minutes of
collection. Optimum fixation time is 12-24 hours, not to exceed 48 hours.
Maintain specimen at room temperature. Please direct any questions regarding
this test to Oncology Customer Service at 800-533-0567.
Breast Cancer Prognosis Profile II
(Paraffin Block) . . . . 495036
Profile Includes
Estrogen/Progesterone Receptor (ER/PR) Assay
HER-2/CEP17 FISH Assay
Specimen Requirement
Tumor (formalin-fixed, paraffin-embedded) in paraffin block transport pouch.
Specimen should be fixed in 10% neutral-buffered formalin within 20 minutes of
collection. Optimum fixation time is 12-24 hours, not to exceed 48 hours.
Maintain specimen at room temperature. Please direct any questions regarding
this test to Oncology Customer Service at 800-533-0567.
Breast Cancer Prognosis Profile III
(Paraffin Block) . . . . 485409
Profile Includes
DNA Ploidy Analysis
Epidermal Growth Factor Receptor (EGFR) Assay
Estrogen/Progesterone Receptor (ER/PR) Assay
HER-2/neu Oncoprotein
Specimen Requirement
Tumor (formalin-fixed, paraffin-embedded) in paraffin block transport pouch.
Specimen should be fixed in 10% neutral-buffered formalin within 20 minutes of
collection. Optimum fixation time is 12-24 hours, not to exceed 48 hours.
Maintain specimen at room temperature. Please direct any questions regarding
this test to Oncology Customer Service at 800-533-0567.
Breast Cancer Prognosis Profile IV
(Paraffin Block) . . . . 485482
Profile Includes
Cathepsin D
DNA Ploidy Analysis
Estrogen/Progesterone Receptor (ER/PR) Assay
Specimen Requirement
Tumor (formalin-fixed, paraffin-embedded) in paraffin block transport pouch.
Specimen should be fixed in 10% neutral-buffered formalin within 20 minutes of
collection. Optimum fixation time is 12-24 hours, not to exceed 48 hours.
Maintain specimen at room temperature. Please direct any questions regarding
this test to Oncology Customer Service at 800-533-0567.
Breast Cancer Prognosis Profile V
(Paraffin Block) . . . . 485383
Profile Includes
Cathepsin D
DNA Ploidy Analysis
Epidermal Growth Factor Receptor (EGFR)
Estrogen/Progesterone Receptor (ER/PR) Assay
HER-2/neu Oncoprotein
Specimen Requirement
Tumor (formalin-fixed, paraffin-embedded) in paraffin block transport pouch.
Specimen should be fixed in 10% neutral-buffered formalin within 20 minutes of
collection. Optimum fixation time is 12-24 hours, not to exceed 48 hours.
Maintain specimen at room temperature. Please direct any questions regarding
this test to Oncology Customer Service at 800-533-0567.
CD4:CD8 Ratio Profile . . . . 505271
Profile Includes
Percentage CD3+CD4+
Absolute CD3+CD4+
Percentage CD3+CD8+
Absolute CD3+CD8+
CD4:CD8 Ratio
CBC With Differential
Specimen Requirement 7 mL
EDTA whole blood (lavender) and 7 mL ACD-A
whole blood (yellow), free from hemolysis. To preserve cellular viability,
collect the specimen so that it will arrive in the laboratory Monday through
Friday and within 24 hours of collection. Maintain specimen at room temperature.
Do
not freeze or refrigerate. Indicate date and
time of collection on the tube(s) and on the request form.
Chronic Lymphocytic Leukemia/Lymphoma Profile, Flow Cytometry . . . . 489088
Profile Includes
Four-color immunophenotyping for the following markers:
CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD22, CD23, CD25, CD33,
CD38, CD45, CD56, FMC-7; kappa and lambda immunoglobulin light chains
Additional markers added as determined by pathologist
(CD71, CD103, CD138, TCR alpha/beta, TCR gamma/delta). Fewer markers will be
analyzed when specimen cellularity is limited.
Specimen Requirement 3 mL
EDTA whole blood (lavender), free from hemolysis, or 2 mL heparinized or EDTA
bone marrow aspirate (green or lavender), or 2 mL EDTA body fluids (lavender)
(large volumes of body fluids should be concentrated to <5 mL), or 0.5-1.0 cm3
fresh tissue in lymph node transport bottle containing RPMI. Submit blood, bone
marrow, and body fluid specimens at room temperature using Leukemia/Lymphoma
Specimen Transport Kit (supplied by LabCorp). Maintain specimens at room
temperature. For fresh tissue, aseptically cut tissue in pieces and place in
lymph node transport bottle. If aspirate is submitted, rinse needle in transport
medium. Submit at room temperature using Leukemia/Lymphoma Specimen Transport
Kit (supplied by LabCorp). If transport kit is not available, place specimen in
sterile container with saline. Submit specimen so it will arrive in the
laboratory Monday through Saturday and within 24 hours of surgical removal. To
avoid transportation delays, submit specimen on the day of collection. If
indicated on request form, testing can be postponed until the laboratory is
notified to continue or cancel the test. Please state on the request form the
date and time of collection and the name and phone number of the pathologist
responsible for the histologic or cytologic diagnosis. Please direct any
questions regarding this test to Oncology Customer Service at 800-533-0567.
Pathologist consultation is available Monday through Friday. Indicate
differential diagnosis on the request form. Submit recent CBC results for
inclusion in report if not submitting whole blood.
Chronic Lymphocytic Leukemia (CLL) Profile, Fluorescence in situ Hybridization (FISH) . . . . 510594
Profile Includes
Fluorescence in situ
Hybridization (FISH) for Chronic Lymphocytic Leukemia (CLL) and Leukemic Phase
of Mantle Cell Lymphoma (11q, 12, 13q, 17p, and CCND1/IgH Fusion)
Specimen Requirement 10
mL (3-5 mL pediatrics) heparinized blood (green) (1 mL minimum) or 1-3 mL bone
marrow aspirate (green) (1 mL minimum) or four slides (two slides minimum) or
one tube fixed-cell pellet from a cytogenetic analysis. Maintain specimen at
room temperature. Indicate pertinent clinical diagnosis and previous cytogenetic
studies on the request form.
Chronic Myelogenous Leukemia Profile: Chromosome Analysis and BCR-ABL FISH . . . . 150410
Profile Includes
BCR-ABL for Chronic
Myelogenous Leukemia (CML), FISH
Chromosome Analysis
Quantitative Monitoring for CML by FISH
ABL deletions are
confirmed by linked ASS analysis
Specimen Requirement 2 mL
heparinized bone marrow or 3 mL heparinized peripheral blood (pediatric green).
Submit at room temperature using Leukemia/Lymphoma Specimen Transport Kit
(supplied by LabCorp). Specimen should arrive in the laboratory within 48 hours
of collection. Maintain specimens at room temperature. Please state the date and
time of collection on the request form. Please direct any questions regarding
this test to Oncology Customer Service at 800-533-0567. Please note that the
chromosome portion of this profile is generally not successful on peripheral
blood samples from CML patients receiving imatinib (Gleevec®).
Colorectal Cancer Monitor Profile . . . . 485011
Profile Includes
Carbohydrate Antigen (CA) 19-9, Serial Monitor Report
Carcinoembryonic Antigen (CEA), Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. State on the test
request form whether the patient is a smoker or nonsmoker. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
Cytology/DNA Ploidy Reflex Profile . . . . 488312
Profile Includes
Cytologic Examination
Prognostic DNA Ploidy Analysis (if atypical or positive
cytologic exam)
Reflex is performed at an additional charge/CPT code(s)
Specimen Requirement Up
to 100 mL voided/catheterized urine or bladder washings
plus an equal volume of fixative; do not send
first morning specimen. Place specimen directly into labeled specimen bottle.
Add equal volume (1:1) of fixative to the patient sample. Invert gently several
times. Add fixative last. Do not add specimen to the
fixative; always add fixative to the specimen. Submit specimen at
room temperature using Cytology/Special Studies Specimen Transport Kit. Maintain
specimen at room temperature. Certain chemotherapeutic agents as well as
radiation therapy may cause cellular atypia that mimics malignant changes.
Please be certain to include on the request form the patient's clinical history,
previous malignancy (history and timing of chemotherapy, radiation therapy
treatments), and the type of specimen. Please direct any questions regarding
this test to Oncology Customer Service at 800-533-0567.
Helper/Suppressor and Natural Killer Profile . . . . 259317
Profile Includes
Percentage CD3+
Absolute CD3+
Percentage CD3+CD4+
Absolute CD3+CD4+
Percentage CD3+CD8+
Absolute CD3+CD8+
CD4:CD8 Ratio
Percentage Natural Killer (NK) Cells
Absolute Natural Killer (NK) Cells
CBC
Specimen Requirement 7 mL
EDTA whole blood (lavender) and 7 mL ACD-A
whole blood (yellow), free from hemolysis. To preserve cellular viability,
collect specimen so it will arrive in the laboratory Monday through Friday and
within 24 hours of collection. Maintain specimen at room temperature. Do
not freeze or refrigerate. Please indicate
date and time of collection on the tube(s) and on the request form.
ImmunoCyt/Urine Cytology Profile . . . . 488148
Profile Includes
Urine Cytology and Immunocytochemistry for Mucin and CEA
Specimen Requirement
Immediately after collection, place up to 40 mL into urine cytology container
and add equal volume of 50% ethanol or 50% isopropanol. Firmly close the
container and mix by inversion. Do
not collect first morning urine sample.
Refrigerate at 2°C to 8°C until shipment to the laboratory. This
procedure must be performed on a sample within 7 days of collection.
Leukemia/Lymphoma Monitor Profile . . . . 485029
Profile Includes
β-2 Microglobulin, Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 2 mL
serum (1 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
Liver Cancer Monitor Profile . . . . 485060
Profile Includes
Alpha-Fetoprotein (AFP), Serial Monitor Report
Carbohydrate Antigen (CA) 19-9, Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
Lung, Adenocarcinoma Monitor Profile . . . . 485078
Profile Includes
Carcinoembryonic Antigen (CEA), Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 3 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If tube other than a
red-top tube is used, transfer the separated serum to a plastic transport tube.
The account must submit the patient's Social Security number to monitor. State
on the request form whether the patient is a smoker or nonsmoker. Values
obtained with different assay methods should not be used interchangeably in
serial testing. It is recommended that only one assay method be used
consistently to monitor each patient's course of therapy.
Lung, Small Cell Cancer Monitor Profile . . . . 485177
Profile Includes
Carcinoembryonic Antigen (CEA), Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Neuron-Specific Enolase (NSE), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. State on the test
request form whether the patient is a smoker or nonsmoker. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
Lymphoma Profile, Fluorescence
in situ Hybridization (FISH) . . . . 510612
Specimen Requirement 10
mL (3-5 mL pediatrics) heparinized blood (green) (1 mL minimum), 1-3 mL bone
marrow (1 mL minimum), four slides (two slides minimum) prepared from a
cytogenetic analysis, fixed-cell pellet prepared from a cytogenetic analysis.
Maintain specimen at room temperature. Indicate pertinent clinical diagnosis and
previous cytogenetic studies on the request form.
Melanoma Monitor Profile . . . . 485037
Profile Includes
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Neuron-Specific Enolase (NSE), Serial Monitor Report
Specimen Requirement 3 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
Multiple Myeloma Profile, Fluorescence in situ Hybridization (FISH) . . . . 510586
Profile Includes
Fluorescence in situ
Hybridization (FISH) for Multiple Myeloma (MM) (Targeting 13q, IgH, CCND1,
FGFR3, TP53)
Specimen Requirement 10
mL (3-5 mL pediatrics) heparinized blood (green) (1 mL minimum) or 1-3 mL bone
marrow aspirate (green) (1 mL minimum) or four slides (3 slides minimum) or one
tube fixed-cell pellet from a cytogenetic analysis. Pediatric Vacutainer™
is optimal. Maintain specimen at room temperature. Indicate pertinent clinical
diagnosis and previous cytogenetics studies on the request form.
Natural Killer Cell and Activated T-Cell Profile/IL-2r . . . . 502500
Profile Includes
Percentage CD3+
Absolute CD3+
Percentage CD3+CD25+
(IL-2r)
Absolute CD3+CD25+
Percentage CD3-CD56+
(NK)
Total CD3-CD56+
(NK)
CBC With Differential
Total Lymphocyte Count
Specimen Requirement 7 mL
EDTA whole blood (lavender) and 7 mL ACD-A
whole blood (yellow), free from hemolysis. To preserve cellular viability,
collect specimen so it will arrive in the laboratory Monday through Friday and
within 24 hours of collection. Maintain specimens at room temperature. Do
not freeze or refrigerate. State date and time
of collection on the request form and on specimen.
Neuroblastoma Monitor Profile . . . . 485052
Profile Includes
Ferritin
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Neuron-Specific Enolase (NSE), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
Ovarian Cancer Monitor Profile III . . . . 485110
Profile Includes
Cancer Antigen 125-II (CA 125), Serial Monitor Report
Carcinoembryonic Antigen (CEA), Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit patient's Social Security number to monitor. State on the request form
whether the patient is a smoker or nonsmoker. Values obtained with different
assay methods should not be used interchangeably in serial testing. It is
recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
Pancreatic Cancer Monitor Profile . . . . 485086
Profile Includes
Carbohydrate Antigen (CA) 19-9, Serial Monitor Report
Carcinoembryonic Antigen (CEA), Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If tube other than a
gel-barrier tube is used, transfer separated serum to a plastic transport tube.
The account must submit the patient's Social Security number to monitor. State
on the request form whether the patient is a smoker or nonsmoker. Values
obtained with different assay methods should not be used interchangeably in
serial testing. It is recommended that only one assay method be used
consistently to monitor each patient's course of therapy.
Prostate Cancer Profile II (Serial Monitor) . . . . 485235
Profile Includes
Prostate-Specific Antigen (PSA), Serial Monitor Report
Prostatic Acid Phosphatase (PAP), Serial Monitor Report
Specimen Requirement 1 mL
serum (0.5 mL minimum - this volume does not allow for repeat testing), free
from hemolysis; refrigerate. Do not use acid
phosphatase transport tube. The account must submit the patient's Social
Security number to monitor. Values obtained with different assay methods should
not be used interchangeably in serial testing. It is recommended that only one
assay method be used consistently to monitor each patient's course of therapy.
T- and B-Lymphocyte and Natural Killer Cell Profile . . . . 505370
Profile Includes
Percentage CD3+
Absolute CD3+
Percentage CD3+CD4+
Absolute CD3+CD4+
Percentage CD3+CD8+
Absolute CD3+CD8+
Percentage CD3-CD56+
Natural Killer (NK) Cells
Absolute CD3-CD56+
Natural Killer (NK) Cells
Percentage CD19+
Absolute CD19+
CD4:CD8 Ratio
CBC
Specimen Requirement 7 mL
EDTA whole blood (lavender) and 7 mL ACD-A
whole blood (yellow), free from hemolysis. Maintain specimen at room
temperature. Do not freeze or refrigerate. To
preserve cellular viability, collect specimen so it will arrive in the
laboratory Monday through Friday and within 24 hours of collection. Please
indicate date and time of collection on the tube(s) and on the request form.
T- and B-Lymphocyte Differential Profile . . . . 096917
Profile Includes
Percentage CD3+
Absolute CD3+ (T Cells)
Percentage CD3+CD4+
Absolute CD3+CD4+
(helper/inducer)
Percentage CD3+CD8+
Absolute CD3+CD8+
(suppressor/cytotoxic)
Percentage CD19+
Absolute CD19+ (B Cells)
CD4:CD8 Ratio
Absolute Lymphocyte Count
CBC With Differential and Platelet Count
Specimen Requirement 7 mL
EDTA whole blood (lavender) and 7 mL ACD-A
whole blood (yellow), free from hemolysis. Maintain specimen at room
temperature. Do
not freeze or refrigerate. To preserve
cellular viability, collect specimen so it will arrive in laboratory Monday
through Friday and within 24 hours of collection. Please indicate the date and
time of collection on the tube(s) and on the request form.
T-Cell Activation Profile, CD8 Subsets . . . . 505750
Profile Includes
Percentage and Absolute Values CD3+,
CD3+CD4+, CD3+CD8+,
CD3+CD25+, CD8+CD38+,
CD8+HLA-DR+, CD4:CD8 ratio
CBC With Differential
Specimen Requirement 7 mL
EDTA whole blood (lavender) and 7 mL ACD-A
whole blood (yellow), free from hemolysis. Maintain specimens at room
temperature. Do
not freeze or refrigerate. To preserve
cellular viability, collect specimen so it will arrive in the laboratory Monday
through Friday and within 24 hours of collection. Indicate date and time of
collection on the tube(s) and on the request form.
Testicular Cancer Monitor Profile . . . . 485151
Profile Includes
Alpha-Fetoprotein (AFP), Serial Monitor Report
β-hCG, Serial Monitor Report
Specimen Requirement 3 mL
serum (1 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
T-Lymphocyte Helper/Suppressor Profile . . . . 096925
Profile Includes
Absolute CD4 Helper/Inducer T Cells (CD3+CD4+)
Absolute CD8 Suppressor/Cytotoxic T Cells CD3+CD8+
Absolute Lymphocyte Count
Absolute T Cells (CD3)
CD4:CD8 Ratio
CBC With Differential and Platelet Count
Specimen Requirement 7 mL
EDTA whole blood (lavender) and 7 mL ACD-A
whole blood (yellow). Maintain specimen at room temperature. Do
not freeze or refrigerate. To preserve
cellular viability, collect specimen so it will arrive in laboratory Monday
through Friday and within 24 hours of collection. Please indicate the date and
time of collection on the tube(s) and on the request form.
Uterine Cancer Monitor Profile . . . . 485136
Profile Includes
Cancer Antigen 125-II (CA 125), Serial Monitor Report
Lipid-Associated Sialic Acid (LASA), Serial Monitor Report
Specimen Requirement 4 mL
serum (2 mL minimum), free from hemolysis; refrigerate. If a red top tube is
used, transfer the separated serum to a plastic transport tube. The account must
submit the patient's Social Security number to monitor. Values obtained with
different assay methods should not be used interchangeably in serial testing. It
is recommended that only one assay method be used consistently to monitor each
patient's course of therapy.
DIAGNOSTIC IMMUNOHISTOCHEMICAL STAINS
(Order test 484006 and specify the stains required.)
Carcinoma Group
• Ber-EP4
• CDX2
• CEA (carcinoembryonic antigen)
• CK 7
• CK 20
• CU-18 (breast-related antigen)
• EMA (epithelial membrane antigen)
• HMW cytokeratin
• LMW cytokeratin
• NSE (neuron-specific enolase)
• OC125 (celomic ovarian antigen)
• P16
• Pancytokeratin (AE1/AE3)
• PSA (prostate-specific antigen)
• PSAP (prostate-specific acid phosphatase)
• TTF-1 (thyroid transcription factor-1)
• Villin
Breast Carcinoma Group
• CU-18 (breast-related antigen)
• ER (estrogen receptor)
• GCDFP-15
• PR (progesterone receptor)
Germ Cell Tumor Group
• AFP (alpha-fetoprotein)
• β-hCG
• CEA (carcinoembryonic antigen)
• Pancytokeratin (AE1/AE3)
• PLAP (placental alkaline phosphatase)
Hematopoietic Group
• CD1a
• CD117
• Myeloperoxidase
• TdT
Hodgkin Disease Group
• CD15 (LeuM1)
• CD20 (Reed-Sternberg cells, B cell, L26)
• CD30 (Reed-Sternberg cells, Ki-1 antigen/BerH2)
Non-Hodgkin Lymphoma Group
• bcl-2
• bcl-6
• CD3
• CD4
• CD5
• CD7
• CD8 (T cell)
• CD10
• CD20, L26 (B cell)
• CD23
• CD43, MTI (T cell)
• CD45, leukocyte common antigen (LCA)
• CD45 RA
• CD45 RO, UCHL-1 (T cell)
• CD74, LN2 (B cell)
• CD79a (B cell)
• CD138
• Kappa light chain
• Lambda light chain
Infectious Disease/Bacterial / Viral
• Helicobacter pylori
• HSV I and II
Liver Group
• A1AT (alpha-1-antitrypsin)
• AFP (alpha-fetoprotein)
• HAM 56
• HepPar-1
• LMW cytokeratin
Melanoma Group
• HMB45
• Mel-5
• Melan-A
• S-100
• Vimentin
Mesothelioma vs Carcinoma Group
• B72.3
• Ber-EP4
• Calretinin
• CD15 (LeuM1)
• CEA (carcinoembryonic antigen)
• CK5&6
• EMA (epithelial membrane antigen)
• Pancytokeratin (AE1/AE3)
• Vimentin
Neuroendocrine Group
• Chromogranin
• NSE (neuron-specific enolase)
• Pancytokeratin (AE1/AE3)
• Serotonin
• Synaptophysin
Pancreatic Group
• NSE (neuron-specific enolase)
• Somatostatin
Prostate Group
• Cytokeratin 903
• P63
• PIN-4 (CK903/P63/Racemase
• (PSA) prostate-specific antigen
• (PSAP) prostate-specific acid phosphatase
• Racemase
Sarcoma Group
• CD31
• CD34
• CD68 (KP-1)
• CD117
• Desmin
• Factor VIII-related antigen
• Factor XIIIa
• HHV-8
• Muscle-specific actin
• Myoglobulin
• S-100
• Smooth muscle actin
• Vimentin
Thyroid Group
• Calcitonin
• CEA (carcinoembryonic antigen)
• Chromogranin
• Thyroglobulin
• TTF-1 (thyroid transcription factor-1)
For information on stains not listed, please call Oncology
Customer Service at 800-533-0567.
*Cytokeratin 903, P63, and racemase, as well as all
lymphoma group stains are available only as Option I or Option II with IV. These
stains cannot be ordered as Option II alone.
ONCOLOGY FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
Diagnostic gene rearrangements at or below the resolution
of cytogenetics may be defined by FISH protocol. Disease-specific translocations
can be detected in nondividing (interphase) cells by implementing multicolor
fluorescence probes specific for the involved genes which reciprocally merge to
form a third color. Oncogenes that have multiple reciprocal translocation sites
can be ultrasensitively evaluated by “break-apart” probes in which
the neoplastic splitting of the critical sequence separates the normal fusion
color into distinct colors regardless of the variant reciprocal site.
Disease-causing deletions relating to the loss of known or putative tumor
suppressor genes (TSGs) are readily identified by the detection of cells with
only a single signal, as in loss of the 5q31 locus-specific probe characteristic
of 5q- syndrome in myelodysplasia. Specially designed
profiles targeting the most common genetic changes can effectively
detect indolent
CLL and myeloma
clones which often have normal cytogenetic analysis that is dependent on
abnormal cell division. An MDS profile can
effectively be used as an interphase adjunct to cytogenetics with no mitotic
activity. Specific genetic changes involved in the initiation and progression of
bladder cancer can effectively be detected by the UroVysion
assay. The CML probes reflex to the argininosuccinate synthetase (ASS) gene
probe to confirm any ABL deletions thought to be associated with poor prognosis
CML by some investigators. A
CML FISH/chromosome analysis profile is
available for monitoring residual disease (marrows).
Opposite-sex bone marrow transplants can be monitored by
either sex chromosome-specific probes or in cases of same-sex transplants, a
leukemic clone-specific probe previously identified by cytogenetics (eg, a
centromere 8 probe for trisomy 8 or BCR-ABL
fusion probes for CML). Molecular engraftment monitoring can be arranged by
calling HLA customer service at 800-533-1037.
Residual disease may also be monitored by clone-specific
probes. These studies offer the advantage of not requiring mitotic cells in the
often hypocellular post-treatment aspirates. Newly available dual fusion and
breakaway probes more accurately rule out low level residual disease by
dramatically reducing background positivity. A new lymphoma
profile with 4 break-apart probes and reflex to 2 dual fusion probes
can reliably identify neoplastic nodes and low level bone marrow involvement.
FISH is also readily applicable to blood smears; touch
preps; formalin-fixed, paraffin-embedded samples; and frozen sections.
See following for available probes and test numbers.
ONCOLOGY-BASED FISH
Test Numbers
| FISH analysis from blood, bone marrow, lymph node or slides (include probe desired): |
510362 |
| FISH analysis ordered in conjunction w/ classical G-band chromosome analysis: |
510362 & 052001 |
| CML PANEL: (BCR/ABL) FISH analysis w/ classical G-band chromosome analysis: |
150410 |
| FISH analysis on paraffin embedded tissue (include probe or panel desired): |
510545 |
